drugset / Trial / NCT00504530

r-hLIF for Improving Embryo Implantation in IVF

NCT00504530 ↗

Phase 1/2 Completed 50 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupDouble-blindTreatment

Summary

This study was designed to obtain pilot clinical evidence of the efficacy, safety and acceptability of r-hLIF administered during the luteal phase after IVF/intra-cytoplasmic sperm injection (ICSI) and ET for improving embryo implantation in infertile women with a history of at least three implantation failures following ART. Based on LIF expression patterns and experimental data from animal research a role of LIF in embryo implantation is anticipated.

Timeline

Start
2001-09
Primary completion
—
Completion
2002-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Emfilermin Protein / enzyme biologic — —

Indications

No indication recorded.